- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.06. | eXoZymes erhält 2 Millionen US-Dollar vom NIH zur Weiterentwicklung von Cannabinoid-Analoga für die Arzneimittelforschung | 1 | Bionity.com | ||
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 26.06. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.06. | Cannabinoid-Forschung: eXoZymes sichert sich NIH-Zuschuss über 2 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 24.06. | exoZymes receives $2M NIH grant for cannabinoid research | 1 | Investing.com | ||
| 24.06. | eXoZymes awarded $2M NIH Grant to advance cannabinoid analogs for drug discovery | 2 | Seeking Alpha | ||
| 24.06. | eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery | 357 | ACCESS Newswire | Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new... ► Artikel lesen | |
| 17.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | eXoZymes schließt Kapitalerhöhung über 5,95 Mio. US-Dollar ab | 2 | Investing.com Deutsch | ||
| 17.06. | eXoZymes closes $5.95M public offering of stock and warrants | 1 | Investing.com | ||
| 17.06. | eXoZymes Inc. Announces Closing of $6 Million Public Offering | 424 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 08.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | eXoZymes prices $5.33M public offering of stock and warrants | 3 | Seeking Alpha | ||
| 08.06. | eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants | 377 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 14.05. | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | eXoZymes Announces Graduation from Shell GameChanger Accelerator Powered by NLR Program | 533 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines... ► Artikel lesen | |
| 07.05. | EXOZYMES INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.04. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast | 832 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 31.03. | eXoZymes Provides Fourth Quarter and Full Year 2025 Update | 354 | ACCESS Newswire | Management to Host Conference Call Today at 5:30 PM Eastern LOS ANGELES, CA / ACCESS Newswire / March 31, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that... ► Artikel lesen | |
| 31.03. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 35,360 | -1,83 % | ANALYSE-FLASH: Berenberg senkt Qiagen auf 'Hold' - Ziel runter auf 40 Euro | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 50 auf 40 Euro gesenkt und die Aktien von "Buy" auf "Hold" abgestuft. Analyst Harry Gillis rechnet mit zunehmendem... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,260 | +2,65 % | Arcutis Biotherapeutics, Inc.: Arcutis Expands Board of Directors with Appointment of Chris Peetz | WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in... ► Artikel lesen | |
| ZENAS BIOPHARMA | 32,360 | +5,41 % | Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| EDGEWISE THERAPEUTICS | 39,580 | +1,98 % | Edgewise Therapeutics Completes $2.65 Billion Deal Of Sevasemten To Servier | ||
| HARMONY BIOSCIENCES | 36,850 | +10,00 % | Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026 | ||
| TANGO THERAPEUTICS | 29,020 | +5,37 % | Mizuho hebt Kursziel für Tango Therapeutics nach vielversprechenden Studiendaten an | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 20,060 | +5,30 % | H.C. Wainwright reiterates Moonlake stock buy rating on funding | ||
| IMMUNOVANT | 39,530 | -0,98 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,630 | +3,47 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ERASCA | 19,405 | +3,11 % | Erasca closes $632.5 million public stock offering | ||
| BEAM THERAPEUTICS | 27,280 | +3,61 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,21 | +0,04 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 18,500 | +6,02 % | Mizuho raises Amylyx stock price target to $24 ahead of trial data | ||
| SUMMIT THERAPEUTICS | 14,620 | +8,30 % | Summit Therapeutics sells ridinilazole to Biossil for $500k | ||
| TARSUS PHARMACEUTICALS | 57,30 | +1,87 % | Guggenheim cuts Tarsus Pharmaceuticals stock price target to $89 |
Das Unternehmen EXOZYMES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,340 (-6,14 %) liegt der Kurs bei 5,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.